Designing and testing single tablet for tuberculosis treatment through electrospinning

Hassounah, Ibrahim; Shehata, Nader; Kimsawatde, Gade Carolyn; Hudson, Amanda G.; Sriranganathan, Nammalwar; Joseph, Eugene G.; Mahajan, Roop L.

doi:10.1016/b978-0-323-41533-0.00011-8

Cited by 6 publications

(4 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Félix et al (2021) reported C=C double bond stretching at 1690 -1635 cm -1 . Peaks at 1241.2 cm -1 , 1148.0 cm -1 , and 1025.0 cm -1 were assigned to C-O stretching and -CH2-bending vibrations, aligning with the findings of Ibrahim et al (2016), who reported C-O stretching at 1200 cm -1 and -CH2-bending vibrations at 1100 -1000 cm -1 . Distinctive peaks at 2851.4 cm -1 , 1543.1 cm -1 , and 1323.2 cm -1 observed in C. procera silver nanoparticles (C.p-AgNPs) disappeared, possibly due to conjugation resulting from synthesis temperature and/or sodium hydroxide addition.…”

Section: Figure 1: Uv Spectrum Of Cp-agnpssupporting

confidence: 85%

Green synthesized silver nanoparticles (AgNPs) using aqueous extract of <i>Calotropis procera</i> and its antimicrobial activity on clinical bacteria isolates

Mamman,

Myek,

Ladan

2024

SWJ

View full text Add to dashboard Cite

The green synthesis of nanoparticles, utilizing aqueous plant extract as a capping and stabilizing agent, has attracted significant attention in various domains, particularly in pharmaceuticals and drug delivery. In this investigation, silver nitrate (AgNO3) salts were employed as precursors to fabricate silver nanoparticles using Calotropis procera (leaves/flower) extract, and the resulting nanoparticles were characterized. Fourier Transform Infrared (FTIR) spectroscopy revealed three primary functional groups at peaks of 2851.4 cm-1, 1543.1 cm-1, and 1323.2 cm-1, responsible for capping and stabilizing the synthesized C.p-AgNPs. Scanning Electron Microscopy (SEM) demonstrated that the synthesized C.p-AgNPs exhibited spherical shapes with an average particle size ranging from 20 nm to 30 nm. Energy-dispersive X-ray (EDX) analysis of the synthesized C.p-AgNPs indicated the presence of pure silver (Ag) at 54.32% in the region of 2.7 to 3.1 keV. Furthermore, the antimicrobial activity of C.p-AgNPs was examined, with the best inhibition observed at 0.5 mg/mL on Gram-negative bacteria S. aureus (12.0 mm) and Streptococcus spp (13.0 mm), and on Gram-positive bacteria E. coli (16.0 mm) and Salmonella spp (14.0 mm). The antimicrobial efficacy was dose-dependent, suggesting the potential for eradicating resistant human pathogenic bacteria. The antibacterial potential of C.p-AgNPs could be enhanced by increasing their concentration, depending on the specific application. Based on the study's findings, C.p-AgNPs derived from Calotropis procera can be employed for various biomedical purposes, such as textile coating by incorporating C.p-AgNPs in fibers and food storage by nanocapsulation of food items to extend their shelf life.

show abstract

Section: Figure 1: Uv Spectrum Of Cp-agnpssupporting

confidence: 85%

Green synthesized silver nanoparticles (AgNPs) using aqueous extract of <i>Calotropis procera</i> and its antimicrobial activity on clinical bacteria isolates

Mamman,

Myek,

Ladan

2024

SWJ

View full text Add to dashboard Cite

show abstract

“…They are consumed daily for 7-14 days [38,39]. Within the eradication scheme, PPIs are used to increase intragastric pH to maintain H. pylori in a replicative vegetative phase [40], whereas the macrolide antimicrobial agent clarithromycin is used to inhibit bacterial protein synthesis [41] and the beta-lactam antimicrobial agent amoxicillin is used to inhibit bacterial cell wall biosynthesis [42]. In addition, because amoxicillin is a broad-spectrum antibiotic used to treat upper and lower respiratory tract, skin, and other infections [43], its consumption is rapidly increasing worldwide [44].…”

Section: Introductionmentioning

confidence: 99%

Abundance and prevalence of ESBL coding genes in patients undergoing first line eradication therapy for Helicobacter pylori

et al. 2023

View full text Add to dashboard Cite

The spread of extended-spectrum beta-lactamases (ESBLs) in nosocomial and community-acquired enterobacteria is an important challenge for clinicians due to the limited therapeutic options for infections that are caused by these organisms. Here, we developed a panel of ESBL coding genes, evaluated the abundance and prevalence of ESBL encoding genes in patients undergoing H. pylori eradication therapy, and summarized the effects of eradication therapy on functional profiles of the gut microbiome. To assess the repertoire of known beta lactamase (BL) genes, they were divided into clusters according to their evolutionary relation. Primers were designed for amplification of cluster marker regions, and the efficiency of this amplification panel was assessed in 120 fecal samples acquired from 60 patients undergoing H. pylori eradication therapy. In addition, fecal samples from an additional 30 patients were used to validate the detection efficiency of the developed ESBL panel. The presence for majority of targeted clusters was confirmed by NGS of amplification products. Metagenomic sequencing revealed that the abundance of ESBL genes within the pool of microorganisms was very low. The global relative abundances of the ESBL-coding gene clusters did not differ significantly among treatment states. However, at the level of each cluster, classical ESBL producers such as Klebsiella sp. for blaOXY (p = 0.0076), Acinetobacter sp. for blaADC (p = 0.02297) and others, differed significantly with a tendency to decrease compared to the pre- and post-eradication states. Only 13 clusters were common across all three datasets, suggesting a patient-specific distribution profile of ESBL-coding genes. The number of AMR genes detected in the post-eradication state was higher than that in the pre-eradication state, which could be attributed, at least in part, to the therapy. This study demonstrated that the ESBL screening panel was effective in targeting ESBL-coding gene clusters from bacterial DNA and that minor differences exist in the abundance and prevalence of ESBL-coding gene levels before and after eradication therapy.

show abstract

“…These are consumed daily for 7-14 days (Malfertheiner et al, 2017;Suzuki et al, 2010). Within the eradication scheme PPI is used to increase intragastric pH to keep H. pylori in a replicative vegetative phase (Ierardi et al, 2019), clarithromycin is a macrolide class antimicrobial agent used to inhibit bacterial protein synthesis (Hassounah et al, 2016) and amoxicillin is a beta-lactam class antimicrobial agent used to inhibit the bacterial cell wall biosynthesis (Karaman, 2015). In addition, since amoxicillin is a broad-spectrum antibiotic used to treat upper and lower respiratory tract, skin and other infections (Castle, 2007), its global consumption rate is increasing rapidly (Browne et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Development and use of an ESBL coding gene panel in patients undergoing first-line eradication therapy for Helicobacter pylori

Gudrā

Silamiķelis

Pjalkovskis

et al. 2022

Preprint

View full text Add to dashboard Cite

The spread of extended-spectrum beta-lactamases (ESBLs) in nosocomial and community-acquired enterobacteria is an important challenge for clinicians due to the limited therapeutic options for infections that are caused by these organisms. The epidemiology of these infections is complex and combines the expansion of mobile genetic elements with clonal spread. Insufficient empirical therapy for serious infections caused by these organisms is independently associated with increased mortality. Here, we developed an ESBL coding gene panel, evaluated the abundance and prevalence of ESBLs encoding genes in patients undergoing H. pylori eradication therapy, and summarized the effect of eradication therapy on gut microbiome functional profiles. To assess the repertoire of known beta lactamase (BL) genes, we divided them in clusters according to their evolutionary relation, designed primers for amplification of cluster marker regions and assessed efficiency of this amplification panel on 120 fecal samples acquired from 60 patients undergoing H. pylori eradication therapy. In addition, fecal samples from additional 30 patients were used to validate the detection efficiency of designed ESBL panel. The presence for majority of targeted clusters was confirmed by NGS of amplification products. Metagenomic sequencing revealed that the abundance of ESBL genes within the pool of microorganisms was very low. The global relative abundances of the ESBL-coding gene clusters did not differ significantly across the treatment states. However, at the level of each cluster, classical ESBL producers, such as Klebsiella sp. for blaOXY (p = 0.0076), Acinetobacter sp. for blaADC (p = 0.02297), and others, differed significantly with a tendency to decrease compared to the pre- and post-eradication states. Only 13 clusters were common among all three datasets, suggesting a patient-specific prevalence profile of ESBL-coding genes. The number of AMR genes detected in the post-eradication state was higher than that in the pre-eradication state, which at least partly might be attributed to the therapy. This study demonstrated that the ESBL screening panel was efficient for targeting ESBL-coding gene clusters from bacterial DNA and that minor differences exist in the abundance and prevalence of ESBL-coding gene levels before and after eradication therapy.

show abstract

Designing and testing single tablet for tuberculosis treatment through electrospinning

Cited by 6 publications

References 69 publications

Green synthesized silver nanoparticles (AgNPs) using aqueous extract of <i>Calotropis procera</i> and its antimicrobial activity on clinical bacteria isolates

Green synthesized silver nanoparticles (AgNPs) using aqueous extract of <i>Calotropis procera</i> and its antimicrobial activity on clinical bacteria isolates

Abundance and prevalence of ESBL coding genes in patients undergoing first line eradication therapy for Helicobacter pylori

Development and use of an ESBL coding gene panel in patients undergoing first-line eradication therapy for Helicobacter pylori

Contact Info

Product

Resources

About